Conjugate of Polyethylene Gylcol and Naloxone and Pharmaceutical Composition and Use Thereof

a technology of polyethylene gylcol and naloxone, which is applied in the field of hydrophilic polymernaloxone conjugate, can solve the problems of side effects that affect the quality of life of patients, ineffective orally administered in the form of tablets, and side effects

Active Publication Date: 2015-02-12
JENKEM TECH CO LTD TIANJIN
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0014]Even more preferably, a, b, c and d may be the same or different, and are each an integer in the range of 0 to 8, 0 to 7, 0 to 6 or 0 to 5.

Problems solved by technology

Therefore, opioid analgesics, having strong analgesic effects on central nervous system, lead to side effects by acting on peripheral opioid receptors.
For patients suffering from chronic pain, in particular, these side effects always affect their quality of life due to chronic administration of opioids for pain relief.
Although naloxone is an opioid receptor antagonist used most widely in clinic practice currently, it is inefficacious when administered orally in the form of tablets due to a significant first pass effect of hepar.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Conjugate of Polyethylene Gylcol and Naloxone and Pharmaceutical Composition and Use Thereof
  • Conjugate of Polyethylene Gylcol and Naloxone and Pharmaceutical Composition and Use Thereof
  • Conjugate of Polyethylene Gylcol and Naloxone and Pharmaceutical Composition and Use Thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of Double-End Substituted Hexaethylene Glycol-Naloxone (α,α)-NAL26 and (β,β)-NAL26 (Compounds E2 and E1, Wherein f=6)

[0031]

Synthesis of Compound B:

[0032]6 g Naloxone hydrochloride A was added into a round bottom flask and dissolved in 30 ml dichloromethane. 11.7 g di-isopropylethylamine (DIPEA) was added after complete dissolution of Naloxone hydrochloride A. The mixture was stirred under nitrogen for 15 min before 7.6 g MEMC1 was added slowly and dropwise into the solution. Then reaction was allowed at room temperature for 24 h. After complete reaction monitored by TLC, stirring was stopped, and water was added three times (30 ml×3) for extraction. The organic phase was washed once with a saturated sodium chloride solution before it was dried over anhydrous sodium sulfate. Concentration and purification by column chromatography offered 5.37 g Compound B with a yield of 87%.

Synthesis of Compound C1 (α Configuration) and Compound C2 (β Configuration):

[0033]5.37 g Compound B...

example 2

Synthesis of Double-End Substituted Tetraethylene Glycol-Naloxone (α,α)-NAL24 (Compound E2, Wherein f=4)

[0039]Except that tetraethylene glycol was used instead of hexaethylene glycol, the procedure of Example 1 was repeated to obtain the double-end substituted tetraethylene glycol-naloxone (α,α)-NAL24. m / z [MH]+ 817. 1H-NMR (CDCl3): 1.14-1.24 (m, 4H), 1.46-1.58 (m, 8H), 2.1-2.23 (m, 4H), 2.52-2.62 (m, 4H), 2.89 (d, 2H), 3.00-3.11 (m, 6H), 3.55-3.78 (m, 16H), 3.86-3.89 (m, 2H), 4.72 (d, 2H), 5.15-5.21 (m, 4H), 5.77-5.85 (m, 2H), 6.50 (d, J=8.16 Hz, 2H), 6.71 (d, J=8.1 Hz, 2H).

example 3

Synthesis of Double-End Substituted Dodecaethylene Glycol-Naloxone (α,α)-NAL212 (Compound E2, Wherein f=12)

[0040]Except that H(OCH2CH2)12—OH was used instead of hexaethylene glycol, the procedure of Example 1 was repeated to obtain the double-end substituted dodecaethylene glycol-naloxone (α,α)-NAL212. m / z [MH]+ 1169. 1H-NMR (CDCl3): 1.12-1.24 (m, 4H), 1.45-1.589 (m, 8H), 2.11-2.24 (m, 4H), 2.50-2.61 (m, 4H), 2.89 (d, 2H), 3.02-3.11 (m, 6H), 3.50-3.78 (m, 48H), 3.86-3.90 (m, 2H), 4.71 (d, 2H), 5.14-5.20 (m, 4H), 5.75-5.85 (m, 2H), 6.51 (d, J=8.17 Hz, 2H), 6.70 (d, J=8.1 Hz, 2H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
pHaaaaaaaaaa
structureaaaaaaaaaa
Login to view more

Abstract

Provided are a PEG-naloxone conjugate of general formula (II) and a pharmaceutical composition comprising the conjugate. In the conjugate, n is an integer in the range of 1-20. Also provided is a three-branched or four-branched conjugate of PEG and naloxone. Structural modification of naloxone with a hydrophilic polymer improves the pharmacokinetic properties of the drug, increase the water solubility of naloxone, improve the in vivo distribution of the drug, reduce the side effects of naloxone on central nervous system, and relieve bowel dysfunction and constipation caused by chronic administration of opioids. Also provided are a pharmaceutical composition comprising the conjugate of the invention and use of the conjugate.

Description

TECHNICAL FIELD[0001]The present invention relates to a hydrophilic polymer-naloxone conjugate, in particular, a conjugate of a small molecular oligomeric ethylene glycol and naloxone, and to a pharmaceutical composition thereofBACKGROUND OF THE INVENTION[0002]Opioid analgesics, such as morphine, are irreplaceable strong analgesics which have been widely used in clinical practice. Data shows that a total of 230 million prescriptions of opioids were written out just in the year 2007 in the US. Opioids mainly act on opioid receptors. Opioid receptors include three types, μ-, δ- and κ-receptors, each includes various subtypes. Opioid receptors exist in central nervous system such as spinal cord as well as peripheral nerves in stomach, small intestine, exocrine glands and the like. Therefore, opioid analgesics, having strong analgesic effects on central nervous system, lead to side effects by acting on peripheral opioid receptors. Primary side effects include opioid-induced bowel dysfun...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K47/48A61K31/485
CPCA61K31/485A61K47/48215C07D519/00A61K47/60A61K47/55A61P1/00A61P1/10A61P25/36
Inventor GUO, ZHIXIONGFENG, ZEWANGXU, LIHUAZHAO, XUAN
Owner JENKEM TECH CO LTD TIANJIN
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap